Valuation: Revance Therapeutics, Inc.

Market Cap 319M 278M 263M 238M 447M 30.6B 449M 3.15B 1.21B 15.56B 1.2B 1.17B 50.06B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 474M 447M 406M 761M 52.14B 764M 5.36B 2.07B 26.51B 2.04B 2B 85.3B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
14.24
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-78.14% 383M
-0.58%+0.43%+31.09%-4.81% 78.35B
-2.55%+6.99%+505.27%+47.92% 61.52B
-1.11%+5.08%-11.47%-33.91% 59.78B
+0.14%-1.20%-11.64%+24.21% 46.53B
-0.24%+1.22%+2.26%+151.03% 45.5B
-1.62%-0.76%+49.85%-14.92% 31.84B
-1.81%+3.16%+45.71%+110.57% 25.4B
+0.47%+3.26%-0.77%+142.41% 21.43B
+0.27%+1.96%+62.19%+102.81% 15.77B
Average -0.68%+1.98%+67.25%+44.72% 38.65B
Weighted average by Cap. -0.92%+2.35%+93.42%+40.15%

Financials

2022 2023
Net sales 133M 116M 109M 99.12M 186M 12.72B 186M 1.31B 505M 6.47B 498M 487M 20.81B 234M 204M 193M 175M 328M 22.46B 329M 2.31B 891M 11.42B 879M 860M 36.74B
Net income -356M -311M -293M -266M -499M -34.2B -501M -3.52B -1.36B -17.39B -1.34B -1.31B -55.95B -324M -283M -267M -242M -454M -31.09B -456M -3.2B -1.23B -15.81B -1.22B -1.19B -50.86B
Net Debt 77.76M 67.81M 64.03M 58.14M 109M 7.46B 109M 767M 296M 3.79B 292M 286M 12.21B 225M 196M 185M 168M 315M 21.54B 316M 2.21B 855M 10.95B 843M 825M 35.24B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!